Conferences - Results from #140

SES AUA 2025: Validation of PAM50 for Predicting Progression in Active Surveillance: Results from the Miami MAST Prospective Clinical Trial March 15, 2025

SES AUA 2025: PSA Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis March 15, 2025

SES AUA 2025: American Urological Association Annual Census Identifies 39% of Practicing Urologists Utilize Unhealthy Coping Mechanisms for Burnout and Stress March 14, 2025

SES AUA 2025: Incidence of New Mental Health Diagnoses in Testicular Cancer Survivors March 14, 2025

SES AUA 2025: Efficacy and Safety of Darolutamide plus Androgen Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase 3 ARANOTE Trial March 14, 2025

SES AUA 2025: Germline Testing for Renal Cancers – How Age and Tumor Characteristics Affect Pathogenic Variants March 14, 2025

SES AUA 2025: Identifying Key Mutations Linked to Metastasis in Clear Cell Renal Cell Carcinoma: A GENIE Database Analysis March 14, 2025

SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC March 14, 2025

SES AUA 2025: Association of Somatic Gene Mutations in Urothelial Cancer Based on Location in the Bladder March 13, 2025

SES AUA 2025: Development and Initial Experience of a Dedicated Female Bladder Cancer Clinical Care Coordinator Role March 13, 2025

SES AUA 2025: Multicenter Experience with First-Line Intravesical Gemcitabine + Docetaxel versus BCG for high risk NMIBC March 13, 2025

SES AUA 2025: Systemic Therapy for Renal Cell Carcinoma with a Tumor Thrombus: Management and Outcomes from the Intercontinental Collaboration on Renal Cell Carcinoma Database March 13, 2025

SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single-Arm, Open-Label, Phase 3 Trial March 13, 2025

SES AUA 2025: LEGEND: Phase 1/2 Study of Detalimogene Voraplasmid, a Novel, Investigational, Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS March 13, 2025

SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC March 13, 2025

SES AUA 2025: Assessing Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from The MAST Trial March 13, 2025

SES AUA 2025: Durability of Nadofaragene Firadenovec Response in Participants with BCG-Unresponsive NMIBC: 36- and 57-Month Follow-Up of a Phase 3 Study March 13, 2025

SES AUA 2025: Survival Outcomes of Radical Prostatectomy versus Dose-Escalated Radiation with ADT in Node-Positive Prostate Cancer March 13, 2025

SES AUA 2025: First-in-Human Study of TAR-210 Erdafitinib Intravesical System in Patients with NMIBC with Select FGFR Alterations March 13, 2025

SES AUA 2025: Long-Term Outcomes of Primary Chemoablation of Low-Grade UTUC with UGN-101, a Mitomycin Reversal Thermal Gel March 13, 2025

Page 8 of 616